Drug Trial Radar · NCT06867718
Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions
Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
267
Actual
Start
Jan 24, 2025
Primary completion
Nov 6, 2025
Study completion Nov 6, 2025
Sponsor
- Lead sponsor
- Regor Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2, 36-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of RGT001-075 in adults who are obese (BMI ≥30 kg/m²) or who are overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. RGT001-075 or matching placebo will be administered once daily.
Conditions
- Obesity or Overweight
Interventions
RGT001-075Drug
RGT001-075 is a small molecule GLP-1 agonist
Placebo ComparatorDrug
Placebo comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in body weight at Week 36Time frame: Baseline and 36 weeks
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
Alliance for Multispecialty Research, LLC
Mobile, Alabama
Synexus Clinical Research
Phoenix, Arizona
Velocity Clinical Research
Huntington Park, California
Angels Clinical Research
Doral, Florida
Optimal Research
Melbourne, Florida
Angels Clinical Research
Miami, Florida
Palm Springs Community Health Center
Miami Lakes, Florida
Synexus Clinical Research
The Villages, Florida
Javara-Privia Medical Group, Georgia LLC
Savannah, Georgia
Javara-Privia Medical Group, Georgia, LLC
Thomasville, Georgia
Synexus Clinical Research
Evansville, Indiana
Velocity Clinical Research
Valparaiso, Indiana
Alliance for Multispecialty Research, LLC
Lexington, Kentucky
Velocity Clinical Research
Baton Rouge, Louisiana
Velocity Clinical Research
Rockville, Maryland
Mankato Clinic-East Main Street-Javara
Mankato, Minnesota
Synexus Clinical Research
Richfield, Minnesota
Synexus Clinical Research
Creve Coeur, Missouri
Velocity Clinical Research
Omaha, Nebraska
Premier Health Research-Sparta-Objective Health
Sparta, New Jersey
Velocity Clinical Research
Vestal, New York
Javara-Tryon Medical Partners, PLLC
Charlotte, North Carolina
Velocity Clinical Research
Durham, North Carolina
Velocity Clinical Research
Cincinnati, Ohio
Velocity Clinical Research
Cleveland, Ohio
Alliance for Multispecialty Research, LLC
Norman, Oklahoma
Velocity Clinical Research
East Greenwich, Rhode Island
Velocity Clinical Research
Dallas, Texas
Synexus Clinical Research
Dallas, Texas
Synexus Clinical Research
San Antonio, Texas
Javara-Privia Medical Group Gulf Coast PLLC
The Woodlands, Texas
Velocity Clinical Research
Waco, Texas
Synexus Clinical Research
Salt Lake City, Utah
Velocity Clinical Research
West Jordan, Utah
Velocity Clinical Research
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.